[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pacing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pacing":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100501937","physiological-vs-right-ventricular-pacing-outcome-trial-evaluated-for-bradycardia-treatment-protect-hf-100501937",false,"NCT05815745","\"Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment\" (PROTECT-HF)","Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment","PROTECT-HF","We will recruit patients who are referred for clinically indicated pacemaker implantation\n\nInclusion Criteria:\n\n1\\. Adults aged over 18 with left ventricular ejection fraction \\>35% and one or more of the following guideline based ventricular pacing indications:\n\n1. Permanent or intermittent 3rd degree AV block\n2. Permanent or intermittent Mobitz type II AV block\n3. First Degree AV block with a pacing indication\n4. Slow chronic Atrial Fibrillation or Proposed AV node ablation\n5. Bifascicular block with a pacing indication\n6. Trifascicular block with a pacing indication\n7. Wenckebach with a pacing indication\n\nExclusion Criteria:\n\n1. Patients who are likely to only need occasional ventricular pacing, i.e. those with isolated sick sinus syndrome.\n2. Pregnant women.\n3. Unable to provide informed consent.\n4. Those with comorbidity leading to a life expectancy \\\u003C1year.","ALL","18 Years",{"count":20,"type":21},2600,"ESTIMATED","INTERVENTIONAL",[24],"NA","The PROTECT-HF multi-centre randomised controlled trial will compare two different pacing approaches for treating patients with slow heart rates. In it the investigators will compare a long-standing standard approach for pacing; right ventricular pacing, with a new form of pacing, physiological pacing (His and Left bundle area pacing) in 2600 patients.\n\nPatients will be allocated at random to receive either right ventricular pacing or physiological pacing. Endpoint measurements will be undertaken at baseline, and at six-monthly intervals post-randomisation. Treatment allocation will be blinded to the endpoint assessor and the patient.\n\nRecruitment and pacemaker implantation will be carried out at each participating centre. The primary analysis will be intention to treat. The investigators will also perform an on-treatment analysis.\n\n2048 patients are needed to detect the expected effect size with 85% power. A total of 2600 patients will be recruited to allow for patient drop-out and crossover.\n\n500-patient sub-study will assess within patient, and between groups, echocardiographic changes over a 24-month period to try and improve mechanistic understanding of PICM (Pacing Induced Cardiomyopathy).",[27,28,29,30,31],"Bradycardia","Pacing","Right Ventricular Pacing","His Bundle Pacing","Left Bundle Branch Area Pacing","RECRUITING","2025-11-21",{"date":35,"type":36},"2025-11-28","ACTUAL",{"date":38,"type":36},"2023-06-05",{"date":40,"type":21},"2029-12-04",{"name":42,"class":43},"Imperial College London","OTHER",45,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100561246","factors-affecting-selection-of-leadless-pacemaker-and-atrioventricular-synchronous-pacing-status-100561246","NCT06587672","Factors Affecting Selection of Leadless Pacemaker and Atrioventricular Synchronous Pacing Status","Factors Affecting Selection of Leadless Pacemaker in Patients With Atrioventricular Block and Atrioventricular Synchronous Pacing Status With a Micra AV: a Multicenter, Prospective, Observational Study","Inclusion Criteria:\n\n1. Patients diagnosed with atrioventricular conduction block, meeting the indications for dual-chamber leadless pacemakers as per the \"Chinese Expert Consensus on Clinical Application of Leadless Pacemakers (2022)\".\n2. Age ≥18 years.\n3. Expected lifespan ≥1 year.\n4. Consent to sign an informed consent form and cooperate in the collection of baseline data and subsequent follow-ups\n\nExclusion Criteria:\n\n1. Patients anticipated to have a high ventricular pacing proportion (\\>40%) and with left ventricular ejection fraction less than 50%.\n2. Patients with persistent atrial fibrillation and a high expected ventricular pacing proportion.\n3. Post-tricuspid valve mechanical valve replacement surgery.\n4. Patients with inferior vena cava pathway anomalies, precluding passage of the leadless pacemaker's delivery sheath.\n5. Patients with an expected lifespan of less than 1 year. 6 Patients who are pregnant, planning pregnancy, or undergoing cardiac transplantation.",{"count":53,"type":21},112,"OBSERVATIONAL","This is a multicenter, prospective, observational study ,the aim of this study is to find factors affecting selection of double-chamber leadless pacemaker in patients with atrioventricular block and ambulatory atrioventricular synchronous pacing status over time using a leadless ventricular pacemaker.",[57,58,59,28],"Pacemaker","Atrioventricular Block","Clinical Trials",[61,62,63,64],"Leadless pacing","Atrioventricular synchrony","Atrioventricular block","Atrial contraction","NOT_YET_RECRUITING","2024-09-04",{"date":68,"type":36},"2024-09-19",{"date":70,"type":21},"2024-09-15",{"date":72,"type":21},"2027-07-31",{"name":74,"class":43},"Xiaohan Fan",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100551990","mechanistic-insights-from-temporary-pacing-in-hfpef-100551990","NCT06467266","Mechanistic Insights From Temporary Pacing in HFpEF","Mechanistic Insights From Multisite Pacing in Patients With Heart Failure With Preserved Ejection Fraction","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 years or above.\n* Formal diagnosis of HFpEF as per ESC guidelines\n* NYHA grade II-IV heart failure symptoms\n* LVEF ≥50%\n* Female participants of child-bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter\n* Able (in the Investigators opinion) and willing to comply with all study requirements.\n* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n\nExclusion Criteria:\n\n* History of persistent or permanent AF\n* Permanent pacing device in situ\n* Female participants who are pregnant, lactating or planning pregnancy during the course of the study.\n* Scheduled elective surgery or other procedures requiring general anaesthesia during the study.\n* Participant who is terminally ill\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Significant peripheral vascular disease precluding an EP study\n* A contraindication to anticoagulation\n* A prosthetic aortic, mitral or tricuspid valve\n* Significant Aortic valve disease\n* Known LV thrombus\n* Insufficient capacity to consent to the study\n* Participation in other studies with active treatment \u002F investigational arm to avoid bias",true,{"count":85,"type":21},10,[24],"Heart failure with preserved ejection fraction (HFpEF) is characterised by impaired diastolic function. A recent clinical trial has demonstrated multiple beneficial outcomes in HFpEF patients receiving personalised accelerated pacing from indwelling permanent pacemakers, including symptomatic improvement, objective reductions in NT-proBNP level and AF-burden.\n\nThe investigators aim to determine the underlying mechanisms behind these documented effects, to investigate the acute intracardiac haemodynamic response to temporary multisite pacing in HFpEF participants and to gain further mechanistic insight with additional haemodynamic, electrical and echocardiographic data collection during temporary pacing in this cohort. This will all provide valuable information towards new potential targets of therapy.",[89,28],"Heart Failure Preserved Ejection Fraction","2024-06-14",{"date":92,"type":36},"2024-06-20",{"date":94,"type":21},"2024-07-01",{"date":96,"type":21},"2026-10-31",{"name":98,"class":43},"Guy's and St Thomas' NHS Foundation Trust"]